Beam Therapeutics Inc
Closed
SectorHealthcare
31.86 7.16
Overview
Share price change
24h
Min
29.78
Max
33.06
Income | -339M -94M |
|---|---|
Sales | -82M 32M |
EPS | -0.91 |
Profit margin | -297.177 |
Employees | 522 |
EBITDA | -362M -102M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +74.27% upside |
Next Earnings | 4 sie 2026 |
|---|
Market Cap | -52M 3B |
|---|---|
Previous open | 24.7 |
Previous close | 31.86 |
Beam Therapeutics Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Beam Therapeutics Inc Forecast
Price Target
By TipRanks
74.27% upside
12 Months Forecast
Average 49.91 USD 74.27%
High 80 USD
Low 26 USD
Based on 12 Wall Street analysts offering 12 month price targets forBeam Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
